This comprehensive review examines the most recent research on all peptides and contrasts their potential and actions. Research shows that incretin mimetics, such as Dulaglutide and Semaglutide, can be drugs that can be used as adjuvants in the investigation of type 2 diabetes.
The following is a review of the two peptides, presented by the most recent research, which compares their potency and potential in detail.
Dulaglutide Peptide: what is it?
One synthetic peptide analog of glucagon-like peptide-1 (GLP-1) is Dulaglutide. A pharmaceutical company developed it in the 2000s. Its unusual formulation extends its half-life to five days. Some of the most interesting aspects of its design are:
- There are two disulfide-linked chains in the peptide, which are very similar GLP-1.
- A modified IgG4-Fc fragment is linked to the two chains using a peptide linker. This modification of IgG4-Fc reduces the immunologic cytotoxicity of the peptide by reducing its interaction with Fc receptors.
- The structure of Dulaglutide is thought to protect against DPP-4 degradation, which can lead to its development. However, the increased size caused by the IgG4-Fc cross-linking reduces its efficiency.
- Studies show that Dulaglutide can activate GLP-1 receptors in several organs, including the pancreas. In research models of type 2 diabetes (T2D), it can help control postprandial glucose by stimulating insulin secretion. The Assessment of Weekly Administration of LY2189265 (Dulaglutide) in Diabetes (AWARD) research program has conducted extensive research on the peptide.
Semaglutide Peptide: What is it?
One peptide analog of GLP-1 is Semaglutide. It was developed in the 2010s, and shares 94% of its molecular structure with GLP-1. With a half-life of five days, the peptide is believed to be the result of many changes:
This compound has been modified to be more resistant to enzyme degradation and to bind to serum proteins. As a result, it has a long half-life. Research shows that following administration, Semaglutide can increase insulin production and help control blood sugar after eating by interacting with GLP-1 receptors throughout the body.
Dulaglutide vs. Semaglutide and Weight
Semaglutide is considered to be effective as an investigational agent in the treatment of obesity and its maintenance in the investigational system after the findings from the phase 3 STEP study. The following is information that researchers investigating the STEP program and the effectiveness of Semaglutide for weight loss should know:
- The STEP program includes ten 3-step studies (STEP 1-10) to determine if Semaglutide works once a week for weight loss.
- From the initial weight of the research population, the peptide has been reported to allow a reduction of 9.6-17.4% over 68 weeks, as published in the STEP trial.
- Research samples of obesity and obesity without type 2 diabetes were enrolled for the main trial, STEP-1; of these, 2/3 were given weekly Semaglutide. At 68 weeks, the peptide was seen to have decreased by 15.0% from the initial weight.
- After 52 weeks at the highest dose of Dulaglutide, the research species in the AWARD-11 study were seen to have lost 5.2% of body weight compared to their initial weight.
Another study showed that Semaglutide appeared to be more effective in weight loss than Dulaglutide. In particular, when comparing Semaglutide and Dulaglutide, the former seemed to lead to greater weight loss.
Dulaglutide vs. Semaglutide and Type 2 Diabetes
For type 2 diabetes, the glycemic control effects of Dulaglutide and Semaglutide have been reported. Low glycated hemoglobin (HbA1c) is one indicator of glycemic control; However, this research shows that Semaglutide can be very effective in this case:
- After 40 weeks of exposure to Semaglutide once a week, the SUSTAIN-FORTE study reported a -2.2% drop in hemoglobin A1c and a 1.9% drop with Semaglutide once a week.
- After 36 weeks of exposure to Dulaglutide every week, the AWARD-11 study showed that baseline HbA1c levels decreased by 1.77%.
- Other studies have also negatively evaluated the efficacy of Dulaglutide and Semaglutide. According to this study, Semaglutide once a week appeared to be more effective than other GLP-1 agonists by a margin of 0.07%.
Buy Semaglutide peptide if you are a licensed professional interested in continuing to learn about this group’s capabilities.
